Eli Lilly is in prime position with its new GIP/GLP-1 launch tirzepatide and its entrenched diabetes blockbuster Trulicity. Chalk it up to a temporary shortage of its...

Eli Lilly is plowing a further $50 million into its research collaboration with Purdue University, signing up to work with its partner for another five years on chall...

Even when a drug’s confirmatory trial fails, the FDA may still give companies a second chance before pulling accelerated approvals. Jazz Pharmaceuticals’ lung cancer ...

In its latest effort to defend against forthcoming Entresto copycats, Novartis is taking to U.S. federal court to allege infringement against several generics players...

As Sanofi looks to step up its vaccine manufacturing game by the middle of the decade, the French Big Pharma is wading into the virtual world. Adding another l...

Women who are looking to get birth control medication without a prescription will have to wait longer than previously expected. The FDA has pushed back a decis...

Following two FDA rejections of novel oral anemia drugs, all eyes are on GSK’s daprodustat. Now, the drug has come out of an FDA panel meeting partially bruised, losi...

Ionis Pharmaceuticals will soon have some new manufacturing digs to help produce its wide range of pipeline meds. Wednesday, the company unveiled plans for a n...

As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winni...

Armed with new data from what Genentech is touting as one of the biggest and most diverse studies of previously treated spinal muscular atrophy (SMA) patients, the Ro...